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The polypeptide exit tunnel is an important functional
compartment of the ribosome where the newly
synthesized proteins are surveyed. The tunnel is
the target of clinically important macrolide antibi-
otics. Macrolides plug the tunnel and are believed
to stop production of all proteins. Contrary to this
view, we show that drug-bound ribosomes can
synthesize a distinct subset of cellular polypeptides.
The structure of a protein defines its ability to thread
through the antibiotic-obstructed tunnel. Synthesis
of certain polypeptides that initially bypass transla-
tional arrest can be stopped at later stages of elonga-
tion while translation of some proteins goes to
completion. Our findings reveal that small-molecule
effectors can accentuate the discriminatory proper-
ties of the ribosomal exit tunnel and that macrolide
antibiotics reshape the cellular proteome rather
than block global protein synthesis.INTRODUCTION
The proteins assembled in the peptidyl transferase center (PTC)
of the ribosome leave through the nascent peptide exit tunnel
(NPET). The 100 A˚ long and 10–20 A˚ wide NPET starts at the
PTC and penetrates through the body of the large ribosomal
subunit (Yonath et al., 1987; Frank et al., 1995; Nissen et al.,
2000; Voss et al., 2006) (Figure 1A). It ensures the successful
passage of newly made proteins out of the ribosome, and thus
is able to accommodate a vast variety of nascent peptide
sequences. The tunnel, however, is not an impartial conduit.
Some nascent peptides can specifically interact with the
NPET, altering the rate of translation elongation and, in extreme
cases, leading to translation arrest. The peptide monitoring and
discriminating properties of the NPET are used by the cell for
optimizing the regulation of gene expression, protein targeting,
and folding (reviewed in Ito et al., 2010). The recognition of the
individual nascent peptide in the NPET and the ribosomal
response can be sensitive to cellular cues, such as the concen-
tration of specific small metabolites. For example, nascent
peptide-mediated translation arrest at the tnaC gene is stimu-508 Cell 151, 508–520, October 26, 2012 ª2012 Elsevier Inc.lated by tryptophan (Gong and Yanofsky, 2002); the concentra-
tion of arginine regulates elongation of the arginine attenuator
peptides in fungi (Fang et al., 2004), while ribosome progression
along the cystathionine g-synthase gene in Arabidopsis is sensi-
tive to the concentration of S-adenosyl-methionine (Onouchi
et al., 2005). In none of these cases is it understood how the
small molecules modulate the progression of the nascent
peptide through the NPET, because their binding sites remain
a mystery.
The ribosomal NPET is the site of action of clinically important
macrolide antibiotics (Va´zquez, 1966) (Figure 1B). The prototype
of this class, erythromycin (ERY), shows strong bacteriostatic
activity against a broad range of Gram-positive and some
Gram-negative pathogens (Oleinick, 1975). The macrolides of
the second generation (e.g., azithromycin) exhibit improved
chemical stability and a superior spectrum of coverage. The
newest generation of macrolides, known as ketolides (e.g.,
telithromycin [TEL]; Figure 1B), is even more potent: they inhibit
bacteria at lower drug concentrations and, in addition, exhibit
increased bactericidal activity against some pathogens (Acker-
mann and Rodloff, 2003; Hamilton-Miller and Shah, 1998).
Treatment of sensitive bacteria with macrolides curtails
protein synthesis and leads to the accumulation of peptidyl-
transfer RNAs (peptidyl-tRNAs) (Brock and Brock, 1959; Men-
ninger et al., 1994; Taubman et al., 1963). ERY also efficiently
inhibits the translation of some synthetic and natural mRNAs
in vitro (Otaka and Kaji, 1975; Starosta et al., 2010; Tenson
et al., 2003). The presence of ERY in a cell-free system abolishes
synthesis of long polypeptides leading instead to production of
peptidyl-tRNAs carrying short (4–10 amino acids long) peptides
(Otaka and Kaji, 1975; Tenson et al., 2003; Va´zquez, 1966).
Mapping the binding site of macrolides in the ribosome has
helped to rationalize these observations (Ettayebi et al., 1985;
Graham and Weisblum, 1979; Moazed and Noller, 1987) (Fig-
ure 1). Macrolides bind in the NPET near the PTC just above
the constriction formed by extended loops of ribosomal proteins
L4 and L22 (Bulkley et al., 2010; Dunkle et al., 2010; Schlu¨nzen
et al., 2001; Tu et al., 2005). Antibiotic binding dramatically
narrows the tunnel, thus hindering the progression of the nascent
peptide. Therefore, it is generally thought that translation is
aborted when the nascent peptide advancing through the
NPET reaches the site of antibiotic binding. The notion that
a macrolide molecule and an extended nascent chain cannot
coexist in the NPET is further supported by the inability of ERY
Figure 1. TheMacrolide Binding Site in the Large Ribosomal Subunit
(A) Binding of the macrolide antibiotics in the NPET obstructs the progression
of the nascent peptide.
(B) Chemical structures of ERY and TEL. Cladinose sugar lacking in ketolides
is boxed.to bind to ribosomes carrying long nascent peptides (Andersson
and Kurland, 1987; Tai et al., 1974). The ‘‘plug-in-the-bottle’’
model of macrolide action implies that these drugs, like the
majority of protein synthesis inhibitors, indiscriminately stop
the production of every protein in the cell during the early stages
of their synthesis.
However, some of the experimental data were hard to recon-
cile with the conventional ‘‘plug’’ model (reviewed in Mankin,
2008). The discovery of drug-dependent ribosome stalling during
translation of short regulatory peptides controlling expression of
macrolide resistance genes raised the possibility of sequence-
specific interactions of antibiotics with the nascent peptide (Ho-
rinouchi and Weisblum, 1980; Mayford and Weisblum, 1989).
This thought was further reinforced by the identification of short
peptides, which could cotranslationally evict macrolide antibi-
otics from the ribosome (Lovmar et al., 2006; Tenson et al.,
1996; Tenson and Mankin, 2001). Several reports also indicated
that the inhibitory effects ofmacrolideson translationof individual
reporters in a cell-free system may vary (Hardesty et al., 1990;
Odom et al., 1991; Starosta et al., 2010; Va´zquez, 1966). Further-
more, the conventional model of macrolide action could not
adequately explainwhy the newer generation of antibiotics (keto-
lides) exhibits improved bactericidal activity against some path-
ogens (Hamilton-Miller and Shah, 1998; Woosley et al., 2010).Although the recent crystallographic studies of the ribosome
complexed with macrolide antibiotics confirmed the notion that
the drug obstructs the NPET (Bulkley et al., 2010; Dunkle et al.,
2010; Schlu¨nzen et al., 2001; Tu et al., 2005), the structures
showed that the bound macrolide molecule leaves a consider-
able amount of room in the NPET. Moore, Steitz, and coworkers
(Tu et al., 2005) proposed that the residual space could be wide
enough to give the nascent peptide an opportunity to slither
through. However, it remained unknownwhether such an oppor-
tunity is ever realized.
In this paper, we demonstrate that macrolides are protein
specific rather than general translation inhibitors, because
some proteins can escape macrolide action by threading
through the drug-obstructed ribosomal tunnel. We further
show that macrolides can arrest translation of some proteins at
the later stages of polypeptide synthesis by locking long nascent
peptides in the NPET. Both the initial protein threading and the
late translation arrest critically depend on the structure of the
antibiotic, the sequence of the nascent peptide, and the archi-
tecture of the NPET itself. Our findings underscore the discrimi-
nating properties of the ribosomal exit tunnel and reveal that
small-molecule effectors can modulate them.
RESULTS
A Selective Subset of Proteins Is Synthesized
in Bacterial Cells Exposed to High Concentrations
of Macrolide Antibiotics
To re-evaluate the mode of translation inhibition by macrolides,
we monitored the incorporation of radioactive [35S]-methionine
into proteins after the exposure of bacteria to an antibiotic. For
these experiments, a macrolide-sensitive Escherichia coli strain
was prepared by inactivating the tolC gene. At the minimal
inhibitory concentration (MIC) of ERY (1 mg/ml) (Table S1 avail-
able online), an expected drop in protein synthesis was observed
(Figure 2A). Raising the ERY concentration to nearly 20-fold the
MIC correlated with a further decrease in protein synthesis down
to 5%–7% of the untreated control. Unexpectedly, however,
further increase in the concentration of the antibiotic had little
effect on the residual translation: cells exposed to 100-fold the
MIC continued to synthesize proteins at 6% of the level of
the control. Even more striking, TEL, the ketolide, known to be
amore potent antibiotic than ERY, permitted a much higher level
of residual protein synthesis: 20%–25% at 100-fold theMIC. The
onset of translation inhibition by macrolides was very rapid and
the maximal level of inhibition was achieved as early as 5 min
after the addition of the drug; however, substantial residual
protein synthesis persisted even after 6 hr of incubation with
the antibiotic (Figure 2B).
Persistent translation in the presence of macrolides could
be accounted for by the accumulation of short peptidyl-tRNA
dropoff products, the low-level expression of all proteins (due
to, e.g., an occasional dissociation of the drug from the trans-
lating ribosomes; Lovmar et al., 2006), or, alternatively, in a
more unconventional scenario, the selective expression of a
subset of polypeptides. In order to discriminate between these
possibilities, we analyzed the proteins synthesized in bacteria
exposed to macrolide antibiotics. Exponentially growing cellsCell 151, 508–520, October 26, 2012 ª2012 Elsevier Inc. 509
Figure 2. The Selective Translation of
Proteins in Cells Exposed to Macrolide
Antibiotics
(A) Residual protein synthesis in the presence of
increasing concentrations of ERY and TEL. Pulse
incorporation of [35S]-methionine in the protein
fraction was determined after 15 min exposure of
macrolide-sensitive DtolC E. coli cells to varying
concentrations of the drugs. Minimal drug inhibi-
tory concentrations DtolC E. coli is 1 mg/ml for ERY
and 0.5 mg/ml for TEL (Table S1).
(B) Residual protein synthesis after exposure of
E. coli cells to the 100-fold MIC of ERY or TEL for
varying times. In (A) and (B), the data points
represent the mean value of residual translation in
two independent experiments with the error
bars representing absolute deviation. The corre-
lation coefficient of the graphs fitted into individual
data sets is 0.98 for ERY and TEL curves in (A) and
0.99 and 0.95 for ERY and TEL curves, respec-
tively, in (B).
(C and D) Analysis of proteins synthesized in E. coli
(C) or S. aureus str. Newman (D) cells treated
with macrolide antibiotics. Pulse-labeled proteins,
isolated from cells exposed for 15 min to the
100-fold MIC of ERY or TEL, were resolved by 2D
gel electrophoresis. The spots representing the
H-NS protein are indicated on the gels by red
arrowheads. The Coomassie-stained gels are
shown in insets.
See also Figures S1 and S2 and Table S1.were incubated with 100-fold the MIC of different macrolides for
15 min (Figure 2B). After pulse labeling with [35S]-methionine, the
proteins newly synthesized in the presence of the drugs were
resolved by 2D gel electrophoresis (Figures 2C, 2D, and S1A).
Under these conditions, synthesis of themajority of cellular poly-
peptides is almost completely inhibited by ERY (Figure 2C) or
azithromycin (Figure S1A). However, a small number of labeled
protein spots were observed, showing that specific polypeptides
continue to be actively synthesized in the presence of the antibi-
otic, albeit at levels somewhat lower compared to the control
cells. The spectrum of proteins synthesized in the presence of
the drug remained largely unchanged even after prolonged
exposure (up to 6 hr) of cells to the antibiotic (Figure S1B). In
agreement with the bulk radiolabel-incorporation experiments
(Figures 2A and 2B), the number of resistant proteins and the
level of their translation in cells exposed to ketolides, such as
TEL and solithromycin, was higher than in cells treated with
ERY or azithromycin (Figures 2C and S1A). Although some
proteins were resistant to all the macrolides tested (Figure S2A,
green circles), many polypeptides exhibited drug-specific resis-
tance (Figure S2A, blue and magenta circles). It appears that the
chemical structure of the drug bound in the NPET defines the
spectrum of the resistant polypeptides. In contrast to macro-510 Cell 151, 508–520, October 26, 2012 ª2012 Elsevier Inc.lides, chloramphenicol, which binds at
the PTC, efficiently inhibited synthesis of
all cellular proteins (Figure S1C). The
protein-specific inhibitory action of mac-
rolides was not limited to the Gram-nega-tive E. coli, but was also observed in theGram-positive pathogen
Staphylococcus aureus str. Newman (Figure 2D), demonstrating
the general nature of the phenomenon.
The N-Terminal Sequence Defines the Protein’s Ability
to Evade Inhibition by Macrolide Antibiotics
To gain insights into the molecular mechanisms of drug evasion
by selected proteins, we examined how ERY affects the transla-
tion of individual polypeptides in vitro. We first identified some
proteins synthesized in E. coli cells exposed to macrolides.
Several spots from the 2D gels (Figure 2C) with the highest rela-
tive radioactivity and electrophoretic mobility similar to the
untreated control were excised and analyzed by mass spec-
trometry. After discarding the proteins with low confidence
scores and spots with ambiguous identity assignments, we
were able to positively identify seven proteins that were resistant
to ERY and 18 that were resistant to TEL (Figure S2A).
Four of the ERY-resistant polypeptides corresponded to the
secreted outer membrane (OmpX, Tsx, BamA) or inner mem-
brane (PspA) proteins whose translation is difficult to reproduce
faithfully in the cell-free system. Of the three remaining cytosolic
proteins, we chose for the subsequent in vitro experiments the
small cytoplasmic protein H-NS (16 kDa), which was expressed
Figure 3. The N-Terminal Amino Acid Sequence of H-NS Renders Proteins Resistant to ERY
(A) The effect of increasing concentrations of ERY on cell-free translation of H-NS, OsmC, and the H-NS18OsmC hybrid. Shown gel bands represent the full-size
[35S]-labeled proteins resolved by SDS gel electrophoresis.
(B) Quantification of the bands from gels in (A).
(C) Synonymous codon substitutions within the twelve 50-terminal hns codons of hns12osmC do not diminish ERY resistance of the hybrid protein in the cell-free
translation system. The nucleotide substitutions in the codon-replacement construct, hns12(CR)osmC, are shown in red.
(D) ERY resistance depends on the number of the N-terminal H-NS amino acid residues appended to OsmC. The hybrid proteins were translated in the E. coli S30
cell-free translation system in the absence or the presence of 50 mM ERY. The bars represent the mean value of residual translation in two independent
experiments with the error bars representing absolute deviation. The correlation coefficient of two individual data sets was 0.97.
(E) ERY sensitivity of the hns12osmC hybrid constructs with different replacements within the N-terminal sequence appended to OsmC. The sequences of 12
N-terminal amino acids are shown at the right. The gels show the full-size hybrid proteins translated in vitro in the absence or the presence of 50 mM ERY.
(F) N-terminal segment of the E. coli protein HspQ (red), that exhibits similarity to H-NS (purple) renders OsmC resistant to ERY. The sequences of H-NS residues
7–12 and HspQ residues 8–13 are shown in bold. The gel shows the [35S]-labeled translation products corresponding to the full-size proteins accumulated in cell-
free translation system in the absence () or presence (+) of 50 mM ERY.
See also Figure S3.in cells treated with all of the tested macrolides (arrowheads
in Figures 2C and S1A). As a control, we used an ERY-sensitive
cytoplasmic protein of comparable size, OsmC (15 kDa).
While the synthesis of OsmC in the E. coli S30 cell-free system
was readily inhibited by ERY (IC50 = 0.8 ± 0.3 mM), translation
of hns was only marginally affected even at higher concentra-tions of antibiotic, thereby recapitulating the in vivo results
(Figures 3A and 3B).
The N terminus of H-NS is the first to encounter the antibiotic in
the NPET and therefore may account for the ability of the protein
to evade the macrolide inhibitory action. We test this idea by
fusing the first 18 codons of hns to the 50 end of the osmCCell 151, 508–520, October 26, 2012 ª2012 Elsevier Inc. 511
Figure 4. ERY Is Retained in the NPET of the Ribosome Synthesizing
the H-NS Protein
Toe-printing analysis of ERY-dependent ribosome stalling within the ErmCL
coding sequence. The 19 codon ermCL gene (lanes 1 and 2) or the hybrid
hns-ermCL constructs (lanes 3 and 4, hybrid with a wild-type hns start codon;
lanes 5 and 6, hybrid with the mutated hns start codon) were translated in the
cell-free translation system in the absence (lanes 1, 3, and 5) or presence
(lanes 2, 4, and 6) of ERY (50 mM). Ribosome stalling within the ermCL
sequence was detected by primer extension. The bands representing ribo-
some stalled within the ermCL sequence are indicated by triangles and the
ermCL codon in the P-site of the stalled ribosome is boxed. The very weak toe-
512 Cell 151, 508–520, October 26, 2012 ª2012 Elsevier Inc.gene and analyzing the translation of the chimeric protein in the
S30 cell-free system in the presence of ERY. The H-NS N
terminus rendered OsmC highly resistant to the drug (Figures
3A and 3B). The resistance of H-NS18OsmC to ERYwas retained
when multiple synonymous codon replacements were intro-
duced in the hns segment of the hybrid mRNA (Figure 3C). This
result indicates that the ability to elude the drug action is associ-
ated with the nascent peptide, rather than with the mRNA
structure. In order to better define the amino acid sequence suffi-
cient for drug evasion, we appended varying number of H-NS
N-terminal residues to OsmC (Figure 3D). Resistance to the anti-
biotic started to increase when seven or more amino acids were
added and saturated upon the addition of 12–15 H-NS residues.
Thus, the resistance determinant resides primarily within the
M1SEALKILNNIR12 N-terminal amino acid segment of H-NS.
Substituting amino acid residues 1–6 with different amino acids
had little effect (Figure 3E). However, replacing the I7LNNIR12
segment of H-NS with the sequence from the susceptible
proteins such as LacZ (S7SSVPG12) or OsmC (G7QAHWE12)
abolished resistance to ERY (Figure 3E). Appending the
MSEALKILNNIR sequence to the OsmC N terminus increased
its resistance to ERY not only in vitro, but also in vivo (Figure S3).
We searched the E. coli proteome for polypeptides whose
N-terminal structure resembles that of H-NS (Kanehisa et al.,
2002). The protein HspQ carries at its N terminus the sequence
I8GQQVR13 whose physicochemical properties are comparable
to the critical sequence I7LNNIR12 of H-NS. Similar to hns, the
in vitro translation of hspQ continued at a high ERY concentra-
tion (data not shown). Furthermore, the 18 amino acid N-terminal
segment of HspQ appended to OsmC rendered the hybrid
protein resistant to the drug (Figure 3F). This result reiterated
the notion that idiosyncratic properties of the N terminus can
render a protein resistant to macrolide antibiotics.
Nascent Peptides Can Bypass the Antibiotic Molecule
in the Ribosomal Tunnel
Different scenarios may account for the ability of a protein to
escape the inhibitory action of macrolides. The N termini of
some nascent peptides could displace the drug from the NPET
(Lovmar et al., 2006; Tenson et al., 1997). The nascent peptide
elongated by a few more amino acids would then prevent
the rebinding of the antibiotic until the completed polypeptide
is released from the ribosome. An alternative scenario is
that some nascent peptides could sneak through the drug-
obstructed NPET without displacing the antibiotic. In order to
assess which of these mechanisms accounts for the resistance
of H-NS to macrolides, we exploited the phenomenon of ERY-
dependent ribosome stalling. The 19 codon open reading frame
(ORF) ermCL regulates the expression of the macrolide resis-
tance gene ermC via programmed translation arrest (Weisblum,
1995). When ERY is bound in the NPET, the ribosome stalls after
polymerizing the ErmCL nascent peptide MGIFSIFVI but no
translation arrest takes place in the absence of the drug (Figure 4,print bands in the start codon mutant sample (lane 6) are likely explained by
low-frequency translation initiation at one of the internal AUG codons of hns.
The cartoons above the gel represent the ermCL (gray bars) and hns (black bar)
ORFs with ERY shown as a star.
lanes 1 and 2) (Horinouchi and Weisblum, 1980; Mayford and
Weisblum, 1989; Va´zquez-Laslop et al., 2008). We fused codons
2–19 of ermCL at the 30 end of the hns gene and tested whether
the ribosome would stall after reaching the ermCL segment of
the hybrid hns-ermCL construct (Figure 4). Primer extension inhi-
bition analysis (‘‘toe-printing’’) (Hartz et al., 1988) yielded the
characteristic band on the gel indicative of the antibiotic-depen-
dent translation arrest within the ermCL gene (Figure 4, lane 4).
Little to no ribosome stalling was observed in the absence of
the drug or when the start codon of the hns-ermCL fusion was
mutated (Figure 4, lanes 3, 5, and 6). This result demonstrated
that ribosomes that have translated the entire H-NS protein fol-
lowed by the ErmCL segment GIFSIFVI retained the ERY mole-
cule bound in the NPET. Because the ribosome carrying a long
nascent peptide is presumed to be refractory to ERY rebinding
(Pestka, 1972; Tai et al., 1974), the most likely explanation of
our results is that the N terminus of the H-NS nascent peptide
threads through the NPET obstructed by the antibiotic.
Selective Discriminating Effects of Macrolide
Antibiotics at the Late Elongation Stages of Protein
Synthesis
Since the opening of the NPET is severely occluded by the
macrolide molecule, negotiating the narrowed tunnel could be
problematic for some natural nascent peptide sequences even
after the initial N-terminal bypass. In order to test whether the
macrolide drug can render the ribosome discriminating at the
later stages of elongation, we analyzed synthesis of several poly-
peptides in the S30 cell-free translation system in the presence
of saturating concentrations (50 mM) of TEL. (This ketolide allows
the synthesis of a larger number of proteins compared to ERY
[Figure 2C], suggesting that more polypeptides would be able
to avoid inhibition at the early rounds of their synthesis.) From
a limited set of examined proteins, the synthesis of the 78 kDa
translation elongation factor EF-G (encoded by fusA) exhibited
an unusual trait. When fusA was translated in the presence of
the antibiotic, synthesis of the full-size EF-G was abolished
and, instead, a polypeptide with an apparent molecular weight
of 40 kDa was generated (Figure 5A). The same product
appeared in the presence of TEL when the 30-truncated versions
of the fusA gene were used as a template indicating that the
drug-induced 40 kDa product corresponds to the N-terminal
segment of EF-G (Figure 5B). This result showed that the ribo-
some with the antibiotic molecule bound in the NPET retains
its discriminating properties long after the initial encounter of
the nascent peptide with the drug.
The precise site of TEL-dependent translation arrest in the
fusA gene was determined by toe-printing. A unique strong
band was observed on the gel in the TEL-containing sample,
indicative of drug-dependent translation arrest at the Glu358
codon of fusA (Figure 5C, lane 2). No ribosome stalling was
observed when the start codon of fusA was disabled by a muta-
tion (Figure 5C, lane 4). Therefore, ribosomes stalled by TEL at
the 358th codon of the wild-type fusA gene should carry
a 358-amino-acid-long nascent peptide.
We further tested whether other macrolide antibiotics can
trigger late translation arrest. To this end, we analyzed in vitro
translation of the 57 kDa protein firefly luciferase (Luc) in the pres-ence of ERY. Translation of wild-type luc is highly sensitive to
ERY and is completely inhibited when the drug concentration
exceeds 1 mM (Figures S4A and S4C). Contrary to the ERY-resis-
tant H-NS18OsmC (Figure 3A), appending the 18 N-terminal
amino acids of H-NS to luciferase failed to rescue the hybrid
protein from antibiotic inhibition (Figures S4B and S4D). Instead,
translation of the hns18luc led to drug-dependent accumulation
of a polypeptide with an apparent molecular weight of 20 kDa
(Figure 5F). This shows that the H-NS18Luc N terminus was
able to bypass ERY in theNPET, but that translation of the protein
was arrested after the synthesis of an 180-amino-acid-long
nascent peptide. In agreement with this notion, the addition of
18 N-terminal amino acids of another ERY-resistant protein,
OmpX, at the beginning of luciferase resulted in the accumulation
of the same 20 kDa product in the presence of ERY (Figure S5D).
Toe-printing analysis revealed formation of ERY-dependent
stalled ribosome complexes at codons Pro189, Pro199, and
Asp205 of the hns18luc hybrid gene (Figure 5G, lane 2). The
start codon mutation (Figure 5G) and the fusion of the hybrid
template with the ermCL reporter (Figures S5A and S5B) demon-
strated that ERY remains bound in the NPET of the ribosome
that comes to a stall after polymerizing a large fragment of the
H-NS18Luc protein. These results confirmed that, similar to keto-
lides, cladinose-containing macrolides can arrest translation
long after the initial threading of the nascent peptide’s N terminus
past the antibiotic.
After the N-terminal bypass, the chances for the drug-bound
ribosome to encounter a problematic nascent peptide sequence
should increase with the length of a polypeptide. Indeed, the
size distribution of the proteins synthesized in the presence of
macrolides is shifted toward lower molecular weights compared
to the no drug control (Figure S2B). The spectra and abundance
of the truncated proteins generated via the N-terminal bypass
and late arrest are yet to be determined. However, the appear-
ance of a number of new protein spots upon exposure of cells
to TEL (Figure S2C) argues that a considerable fraction of trun-
cated polypeptides can be generated in the bacterial cell during
treatment with some macrolide antibiotics.
Antibiotic-Induced Ribosome Stalling Depends
on the Structure of the Nascent Peptide
In the stalled ribosome complex, four to five C-terminal amino
acid residues of a nascent peptide are able to directly interact
with the macrolide antibiotic (Tu et al., 2005; Va´zquez-Laslop
et al., 2008, 2011a) and may play an important role in the late
translation arrest. To test whether the peptide structure defines
the site of late arrest, we modified the sequence of ten EF-G
amino acids (residues 348–357) at the site of TEL-dependent
arrest (Figure 5D). The alteration in the nascent peptide structure
was introduced by compensatory frameshift mutations in
the fusA gene, which changed the sequence of this segment
of EF-G with a minimal effect upon the structure of mRNA.
This change in the structure of the nascent peptide prevented
TEL-dependent ribosome stalling at the Glu358 codon of fusA.
(The synthesis of the full-size EF-G was not completely restored
because the alleviation of stalling at the Glu358 codon unmasked
downstream late-arrest sites leading to the production of
a longer, yet incomplete protein [Figure 5D].)Cell 151, 508–520, October 26, 2012 ª2012 Elsevier Inc. 513
Figure 5. Selective Late Translation Arrest Induced by Macrolide Antibiotics
(A) TEL-dependent arrest of fusA translation in the cell-free system. The fusA gene was translated in vitro in the absence or presence of 50 mM TEL and the
reaction products were resolved by SDS gel electrophoresis. The full-length EF-G and the truncated translation product are indicated by black and gray arrows,
respectively, in (A), (B), (D), and (E).
(B) Translation of EF-G and its C-terminally truncated mutants in the absence () or presence (+) of TEL. The number of deleted C-terminal residues is indicated.
(C) Detection of the site of TEL-dependent ribosome stalling in the fusA gene by toe-printing. The wild-type fusA gene (lanes 1 and 2), the start codon mutant
(lanes 3 and 4) and the frameshift mutant in which the amino acid residues 348-357 were changed (lanes 5 and 6) were used as templates in a cell-free translation
reaction in the absence () or presence (+) of 50 mMTEL. Ribosome stalling was detected by primer extension. The toe-printing band is indicated by a triangle and
the fusA codon (Glu358) located in the P-site of the stalled ribosome is boxed.
(D) SDS gel electrophoresis analysis of the products of in vitro translation of wild-type fusA (lanes 1 and 2) or the frameshift mutant (lanes 3 and 4) in the absence or
presence of TEL. A new TEL-dependent incomplete translation product of the frameshift mutant is indicated by a bicolored arrow.
(E) The A2062U mutation reduces efficiency of TEL-dependent late translation arrest. SDS gel electrophoresis analysis of the products of translation of fusA by
wild-type or mutant (A2062U) ribosomes in the absence or presence of a saturating concentration of TEL (50 mM).
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ERY-dependent late translation arrest within the hns18-luc
open reading frame occurs at three sites: Pro189, Pro199, and
Asp205. (Figure 5G, lane 2). When a compensatory frameshift
mutation altered the residues 180–188 of the H-NS18Luc nascent
peptide, ribosome stalling at the Pro189 codon was dramatically
reduced (Figure 5G, lane 6). In contrast, translation arrest at the
two downstream sites, Pro199 and Asp205, was not affected.
These results demonstrate that late translation arrest depends
on the nascent peptide structure and occurs when a ‘‘problem-
atic’’ aminoacid sequenceadvances from thePTC into theNPET.
The Structure of the NPET-Bound Antibiotic Influences
the Late Translation Arrest
The structure of the macrolide molecule may impact the effi-
ciency and selectivity of the late translation arrest (Va´zquez-
Laslop et al., 2011b; Weisblum, 1995). In order to test this
concept, we compared the ability of five different macrolides
to trigger late ribosomal stalling at the hns18lucmRNA. Although
all these antibiotics readily inhibited in vitro translation of the
wild-type luciferase only four of the five tested macrolides
(ERY, clarithromycin, TEL, and CEM-112) promoted the accu-
mulation of a 20 kDa late-arrest translation product (Figure S4F).
No truncated polypeptide product was observed in the presence
of troleandomycin (Figures 5F and S4F), and, as a result, this
drug had little effect on expression of the functionally active
enzyme from the hns18luc template (Figure S4D). Toe-printing
confirmed that the efficiency of troleandomycin-dependent ribo-
some stalling was dramatically reduced compared to ERY (Fig-
ure 5G, lanes 8 and 9). The use of the C-terminal ErmCL reporter
showed that troleandomycin remains bound to at least a fraction
of the translating ribosomes (Figure S5C). We concluded that
changes in the structure of the NPET-bound antibiotic may affect
the sequence specificity of late translation arrest.
The Efficiency of Late Ribosome Stalling Depends
on the Structure of the Exit Tunnel
The shape of the NPET opening is likely critical for the progres-
sion of the newly synthesized protein. Therefore, we tested
whether alterations in the NPET structure would affect the
nascent peptide-discriminating properties of the drug-bound
ribosome. For that, the fusA gene was translated in a cell-free
system by either wild-type ribosomes or ribosomes carrying
the 23S ribosomal RNA (rRNA) mutation A2062U (Figure S6A).
Although this mutation did not confer TEL resistance (Table S1)
or prevent antibiotic binding (Figure S6C), it significantly reduced
the accumulation of the TEL-dependent 40 kDa truncated
product, consequently increasing the amount of full-size EF-G
(Figure 5E). Furthermore, the spectra of ERY-resistant proteins(F) ERY-induced late translation arrest within the hns18luc chimeric gene. SDS gel
in the presence of increasing concentrations of ERY (top gel) or troleandomycin (bo
truncated polypeptide is indicated by the gray arrow.
(G) Mapping the sites of ERY-dependent late translation arrest in the hns18luc gen
and 4) and the frameshift mutant in which the amino acid residues 180–188 were
(lanes 1, 3, 5, and 7) or the presence of ERY (lanes 2, 4, 6, and 8) or troleandomyc
Three prominent stalling sites are indicated by purple, blue, and brown triangles;
boxed with the same color in the luc sequence shown below.
See also Figures S4, Figures S5, and Figures S6.synthesized in wild-type cells and in mutants with tunnel muta-
tions A2062G or U2609C showed considerable variation (Fig-
ure S6B). Altogether, these results demonstrate that the NPET
structure directly influences the selective translation properties
of the antibiotic-bound ribosome.
DISCUSSION
Discriminating properties of the NPET allow the ribosome to
modulate its functions in a protein-specific manner, depending
on the nascent peptide sequence (Nakatogawa and Ito, 2002).
In this paper, we show that small molecules can globally influ-
ence the differentiating capacity of the ribosomal tunnel.
For a long time, macrolide antibiotics have been considered to
be general inhibitors of translation that prevent the synthesis of
all cellular proteins by plugging the ribosomal tunnel. In contrast
to this prevailing view, we demonstrated that the mode of action
of these drugs is protein specific.
With the macrolide antibiotic bound in the NPET, the structure
of the nascent peptide N terminus determines whether protein
synthesis is aborted, stalled, or continued. When the protein
chain grows to five to ten amino acids and reaches the site of
the antibiotic binding in the NPET, translation of many polypep-
tides is aborted because the peptidyl-tRNA dissociates from the
ribosome (Menninger, 1995; Tenson et al., 2003) (Figure 6A). A
small number of specific short nascent peptides, like those en-
coded in the regulatory cistrons of macrolide resistance genes,
can instead stall the ribosome, which retains peptidyl-tRNA but
is unable to catalyze the peptide bond formation (Horinouchi
and Weisblum, 1980; Ramu et al., 2011; Va´zquez-Laslop et al.,
2008). In either of these scenarios, the nascent chain cannot
bypass the antibiotic obstacle in the NPET, and protein expres-
sion is curtailed. However, due to the phenomenon of the
N-terminal bypass, some peptide sequences have the ability
to thread through the antibiotic-occupied NPET (Figure 6A),
leading to the synthesis of long polypeptides on drug-bound
ribosomes.
Crystallographic structures of ribosome-macrolide complexes
show that macrolides do not completely block the tunnel, but
leave an opening that may provide a passage for the nascent
peptide (Figures 6B and 6D) (Bulkley et al., 2010; Dunkle et al.,
2010; Schlu¨nzen et al., 2001; Tu et al., 2005). With limited
gymnastics, even the bulkiest amino acid residues could pass
through the constriction of the drug-obstructed NPET. The aper-
ture of the opening is controlled by the placement of a highly flex-
ible rRNA residue A2062 (Fulle and Gohlke, 2009; Seidelt et al.,
2009; Va´zquez-Laslop et al., 2008). In the absence of a nascent
peptide, A2062 comes into close contact with the macrolideelectrophoresis analysis of the products of translation of the hns18luc template
ttomgel). The full-size protein is indicated by the black arrow; the ERY-induced
e. The hns18luc template (lanes 1, 2, and 7–9), the start codon mutant (lanes 2
changed (lanes 5 and 6) were translated in a cell-free system in the absence
in (lane 9), and the site of ribosome stalling was analyzed by primer extension.
the codons in the P-site of the corresponding stalled ribosomal complexes are
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Figure 6. TheMode of Binding and Action of
Macrolide Antibiotics
(A) Previously known and new modes of action of
macrolide antibiotics. (1) The dropoff of peptidyl-
tRNA at the early rounds of translation. (2) Early
ribosome stalling (e.g., during translation of regu-
latory peptides controlling macrolide resistance
genes). (3) N-terminal bypass. (4) Late arrest after
the N-terminal bypass. (5) Expression of the full-
size protein by the drug-bound ribosome. The
nascent peptide N-terminal sequence prone to
dropoff is shown in yellow, the N-terminal bypass-
promoting sequence is green and the peptide
segments directing early or late translation arrest
are red. Themacrolide antibiotic is shown as a star.
(B) Themacrolide molecule leaves sufficient space
for the nascent peptide in the NPET. The cross-cut
of the NPET along the tunnel axes (left) and
perpendicular to the tunnel axes (right) of the
E. coli ribosome complexed with ERY (Protein
Data Band ID Code [PDB] 3OFR) (Dunkle et al.,
2010). ERY is colored in salmon and the position of
the perpendicular cross-cut planes relative to the
drug are shown by dotted lines.
(C) Gating of the drug-obstructed tunnel by A2062.
In the absence of the nascent peptide, A2062
comes into a close contact with the macrolide
narrowing the opening of the NPET (gray carbon
atoms, PDB 3OFR; Dunkle et al., 2010). In the
presence of the nascent peptide, the residue can
potentially reorient to open up the tunnel space.
The orientation shown for A2062 (green carbon
atoms) corresponds to the placement of the
residue in the Haloarcula marismortui large ribo-
somal subunit complexed with the transition state
analog (PDB 1VQ7; Schmeing et al., 2005).
(D) Possible simultaneous placement of a macro-
lide and nascent peptide in the NPET. A cross-cut
of the large ribosomal subunit complexedwith ERY
(salmon) with the modeled 12-amino-acid-long
nascent peptide esterifying the P-site tRNA (cyan).
See also Figure S6.molecule, occluding the tunnel lumen (Figures 6B and 6C)
(Tu et al., 2005). Some nascent peptides might force the A2062
base to reposition closer to the NPET wall, which would open
a larger space in the NPET facilitating the passage of the poly-
peptide chain (Schmeing et al., 2005) (Figure 6C). The important
role of A2062 in nascent peptide surveillance is further
emphasized by the fact that its mutation alleviates both early
ERY-dependent ribosome stalling at the regulatory ORFs of
macrolide resistance genes (Va´zquez-Laslop et al., 2008,
2010), as well as TEL-dependent late translation arrest within
the fusA gene (Figure 5F).
In addition to gating the tunnel, A2062, which may allosteri-
cally influence the catalytic properties of the PTC in a peptide-
dependent manner (Va´zquez-Laslop et al., 2008, 2010), could
play a role in the kinetic control of the N-terminal bypass.
When the short nascent peptide reaches the tunnel constriction
formed by the antibiotic and A2062, subsequent events likely
depend on the relative rates of peptidyl-tRNA dropoff, dissocia-
tion of the drug, or threading of the peptide through the opening
of the antibiotic-obstructed tunnel. It is conceivable that slowing516 Cell 151, 508–520, October 26, 2012 ª2012 Elsevier Inc.down peptide bond formation in response to specific nascent
peptide sequences can abort translation via peptidyl-tRNA
dropoff or ribosome stalling. Alternatively, if peptide elongation
is kinetically favored, threading the peptide through the tunnel
constriction would aid the retention of peptidyl-tRNA in the
ribosome, and translation would continue on the drug-bound
ribosome. In this regard, it is noteworthy that the bypass directed
by the N terminus of H-NS is much more pronounced in the
‘‘fast’’ S30 cell-free translation system compared to the less
efficient in vitro system prepared from purified components
(Hillebrecht and Chong, 2008).
The protein’s N terminus determines its ability to bypass the
macrolide molecule and the A2062 gate in the NPET. The broad
functional spectrum of macrolide-resistant proteins (Figure S2A)
argue that it is the local structure of the N-terminal sequence
rather than protein function that defines the propensity for
the bypass. As few as 12 N-terminal amino acids of H-NS
(MSEALKILNNIR) are sufficient for rendering a macrolide-sensi-
tive protein (OsmC) highly resistant to the drug. Within the H-NS
N-terminal structure, the first six N-terminal amino acids appear
to be fairly inconsequential whereas the segment I7LNNIR12
plays more important role in antibiotic evasion because its
replacement with an unrelated sequence dramatically reduced
theN-terminal threading capacity (Figure 3E). In contrast, alanine
substitutions of individual amino acids had little effect on bypass
(data not shown). Either a particular folding of this segment or the
cumulative effects of specific contacts of several amino acid
residues with the ribosome and/or the antibiotic appear to be
required for efficient threading of the peptide through the drug-
obstructed tunnel. Any of these mechanisms may either orient
the peptide’s N terminus for slithering through the narrow
gap of the antibiotic-occupied NPET or modify the shape of
the tunnel (e.g., inducing the reorientation of A2062) and/or the
pose of the antibiotic, thereby facilitating the bypass. In the
mature H-NS protein, the I7LNNIR12 sequence folds into a unique
‘‘kinked’’ a helix stabilized by interactions with the second H-NS
molecule (Bloch et al., 2003). It is unlikely, however, that such
a structure is possible within the confines of the NPET.
None of the N-terminal sequences of the other ERY- or TEL-
resistant proteins that we identified in the 2D gel spots (Fig-
ure S2A) closely matches that of H-NS. Therefore, it is obvious
that the sequence constraints for the N-terminal bypass are fairly
relaxed, especially in the case of ketolides, which allow the
escape of many more polypeptides. We noted, however, that
N-terminal segments of several of the resistant proteins contain
a stretch of two to three hydrophobic residues followedby aposi-
tively charged amino acid (underlined in Figure S2A). It remains
to be determined whether this feature is one of the drug-evasion
determinants.
The presence of an antibioticmolecule in theNPET renders the
ribosome selective not only at the beginning of protein synthesis,
but also during later stages of the nascent peptide polymeriza-
tion. Following the N-terminal bypass, translation of some poly-
peptides can continue unimpeded, whereas elongation of other
proteins can be arrested at a subsequent phase, leading to the
phenomenon of macrolide-dependent late translation arrest.
Similar to the N-terminal bypass, the structure of the nascent
peptide, and more specifically of its PTC-proximal segment, is
the key factor in defining the site of the late arrest; altering a short
C-terminal nascent peptide sequence at the arrest site (Figures
5D and 5H) can alleviate ribosome stalling. Although the molec-
ular mechanism of the late arrest remains to be investigated, we
noted that the site of the TEL-dependent arrest within the fusA
gene (Arg357-Glu358-Arg359, with the Glu codon positioned in
the P-site of the stalled ribosome) resembles the conserved
motif (Arg-Leu-Arg) of the ‘‘RLR’’ class of short stalling peptides
of the induciblemacrolide resistance genes (Ramu et al., 2009). It
is possible, therefore, that the basic principles of the late trans-
lation arrest and the early drug-dependent ribosome stalling
are generally similar.
Peptide surveillance properties of the ribosome are directly
affected by the structure of the tunnel-bound small-molecule
effectors. Ketolides, which lack the bulky C3 cladinose, permit
the synthesis of many more proteins than cladinose-containing
macrolides (Figures 2C, 2D, and S1A). Other variations in the
drug structure can also influence the discriminating properties
of the NPET (Figures 5G, S4D, and S4F) either directly, by
changing the shape of the tunnel aperture and idiosyncraticinteractions with the nascent peptide, or by altering the site of
the drug binding in the NPET (Berisio et al., 2003). An important
concept that emerges from this result is that by modifying the
structure of the tunnel-bound antibiotic, or in more general
terms, of any small molecule that binds in the NPET, it is possible
to deliberately alter the spectra of the proteins translated by the
ribosome.
The macrolide-mediated selectivity of translation can be addi-
tionally affected by extraribosomal cues. Several secreted
proteins, including OmpX, were actively synthesized in E. coli
exposed to ERY (Figure S2A) but their translation was inhibited
in cell-free system. Although fusion of the N-terminal 18 amino
acid segment of OmpX to luciferase promoted the N-terminal
bypass (Figure S5D), the in vitro translation of the full-size
OmpX protein remained sensitive to ERY likely due to late trans-
lation arrest (data not shown). Interaction of the OmpX nascent
peptide with the cytoplasmic components of the secretion
machinery (Huber et al., 2011) and/or the pulling force of the
translocon (Chiba et al., 2011; Nakatogawa and Ito, 2002) could
facilitate the bypass of the late-arrest site(s), thus ensuring the
successful elongation of the membrane protein in vivo.
The selective N-terminal bypass and late translation arrest can
account for some previously puzzling results. The long-known
resistance of polyU translation to ERY (Hardesty et al., 1990;
Va´zquez, 1966) and a more recently reported poor inhibition of
in vitro synthesis of green fluorescent protein (GFP) by macro-
lides (Starosta et al., 2010) can be easily rationalized if one
assumes that poly(Phe) and GFP could thread through the mac-
rolide-occupied NPET. A number of other results, from the accu-
mulation of long peptidyl-tRNA (Menninger et al., 1994; Yao
et al., 2008), to the persistence of polysomes in ERY-treated cells
(Ennis, 1972), to the ERY resistance caused by ribosomal protein
L22 mutations (Apirion, 1967; Chittum and Champney, 1994;
Lovmar et al., 2009; Moore and Sauer, 2008), which were hard
to explain within the confines of the conventional model of mac-
rolide action, now could be rationalized in view of our findings.
The understanding that macrolides do not block synthesis of
all the proteins, but rather convert the universal translation
machine into a selective producer of certain polypeptides, has
important clinical implications. Ketolides are much more potent
antibacterials than the drugs of previous generations. Further-
more, ketolides exhibit increased bactericidal activity against
some Gram-positive bacteria (Hamilton-Miller and Shah, 1998;
Woosley et al., 2010; Zhanel and Hoban, 2002). Strikingly, keto-
lides license continued synthesis of by far more proteins than
ERY or azithromycin (Figures 2C, 2D, and S1A). It appears that
blocking the expression of only a part of the cellular proteome
could be more fatal to the cell than a complete or near-complete
inhibition of translation. Preventing translation of only a subset of
proteins will interrupt biochemical pathways at random steps
leading to the accumulation of potentially toxic metabolic inter-
mediates or depletion of essential cofactors, which may trigger
a lethal cellular response (Kohanski et al., 2007). In contrast, in-
hibiting synthesis of all the proteins would eventually deprive the
cell from its biosynthetic and metabolic capacity, leading to
bacteriostasis. Noteworthy, whereas most of the ‘‘global’’
protein synthesis inhibitors are bacteriostatic, aminoglycosides
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prone are strongly bactericidal (Va´zquez, 1979). The production
of truncated polypeptides generated via late translation arrest
could be another important factor contributing to the increased
potency of ketolides.
The new insights into the mode of action of macrolide
antibiotics offer novel directions for drug discovery. Optimizing
the tunnel-bound antibiotics for inhibiting specific proteins
may increase the cidality of the drugs, thereby improving
the outcomes of antibiotic therapy. Furthermore, identifying
small molecules that modulate the translation of individual
proteins in the eukaryotic cell by binding in the NPET of the
eukaryotic ribosome can find application in broad areas of medi-
cine (Peltz et al., 2009).
EXPERIMENTAL PROCEDURES
Metabolic Labeling of Proteins
The macrolide-hypersusceptible tolC- E. coli strain BWDK was prepared by
curing the resistance marker in the BW25113-derived tolC::kan strain (Baba
et al., 2006). BWDK cells, exponentially growing in 100 ml of M9 medium
supplemented with 40 mg/ml of all amino acids except methionine (M9AA-M),
were exposed to 1- to 100-fold MIC of each antibiotic (1–100 mg/ml for ERY or
0.5–50 mg/ml for TEL) for 15 min, after which 1 mCi [35S]-methionine (specific
activity 1,175 Ci/mmol) was added, and the cells were incubated for one
more minute. The proteins were precipitated by adding an equal volume of
ice-cold 25% trichloroacetic acid (TCA) containing 2% casamino acids. After
incubating for 30 min on ice and then 30 min at 100C, samples were passed
through G4 glass fiber filters. The filters were washed three times with 3 ml of
ice cold 5% TCA, and once with 3 ml of acetone and air dried, and the amount
of retained radioactivity was determined by scintillation counting. The data
were normalized relative to the ‘‘no drug’’ control.
2D-Gel Electrophoresis Analysis of the Radiolabeled Proteins
Exponentially growing cultures (50 ml) of E. coli (strain BWDK, M9AA-M
medium) or S. aureus (strain Newman, CDM-M medium; Hilliard et al., 1999)
were incubated with 100-fold MIC of ERY (100 mg/ml for E. coli; 25 mg/ml for
S. aureus), TEL (50 mg/ml for E. coli; 12.5 mg/ml for S. aureus), azithromycin
(100 mg/ml for E. coli), or solithromycin (50 mg/ml for E. coli) for 15 min. [35S]-
methionine (250 mCi, specific activity 1,175 Ci/mmol) was then added, and
the cells were incubated for 3 min, followed by the addition of unlabeled
L-methionine to final concentration of 80 mg/ml and further incubation for
7 min. The cells were pelleted by centrifugation at 4,000 3 g for 15 min at
4C. The E. coli cells were lysed by boiling 5 min in buffer containing 60 mM
Tris (pH 6.8), 5% SDS, and 10% glycerol. S. aureus cells were lysed by
incubation in the lysis buffer (Tris-HCl [pH 7.5], 30 mM MgCl2, 30 mM
NH4Cl, 0.1 mg/ml lysostaphin, 100 U of Omnicleave endonuclease (Epicenter)
at 37C for 30 min. The lysates were centrifuged and the supernatant was
passed through a 0.22 mm filter. The extracted proteins (600 mg [E. coli] or
200 mg [S. aureus]) were fractionated by two-dimensional gel electrophoresis
(O’Farrell, 1975) at Kendrick Labs, Inc. (Madison, WI). The gels were stained
with Coomassie brilliant blue, dried, and exposed to the phosphorimager
screen overnight.
Protein Identification
The radiolabeled spots in the 2D gels containing ERY- or TEL-treated samples
were computationally correlated with the Coomassie-stained, nonradiola-
beled 2D gels. The stained protein spots were cut out and subjected to
LC/MS/MS analysis at the Proteomics facility of the University of Illinois at
Chicago.
Cell-Free Protein Synthesis and Analysis of Translation Products
In vitro translation was carried out in the E. coli S30 cell-free transcription-
translation system for linear templates (Promega). PCR-generated DNA
template (0.1–0.5 pmol) carrying the desired gene under the control of the
Ptac promoter was translated in a 5 ml reaction containing 2 mCi [35S]-methio-518 Cell 151, 508–520, October 26, 2012 ª2012 Elsevier Inc.nine (specific activity 1,175 Ci/mmol) following the manufacturer’s protocol.
After 30–45 min incubation at 37C, the reactions were treated with 0.5 mg
RNase A for 5 min at 37C and precipitated with four volumes of ice cold
acetone. Proteins were fractionated in a 16.5% polyacrylamide gel using the
Tricine-SDS buffer system (Scha¨gger and von Jagow, 1987). Gels were dried
and exposed overnight to a phosphorimager screen. The bands were quanti-
fied using the ImageJ software (http://rsbweb.nih.gov/ij/). The background
intensity was subtracted and the integrated density values were normalized
relative to the no-drug control. The normalized band intensity values were
fitted to a sigmoidal dose response curve (95% confidence level) using the
Prism software (GraphPad).
The activity of in vitro translated firefly luciferase was determined using the
Luciferase Assay Reagent (Promega) as recommended by the manufacturer.
Toe-Printing Assay
The toe-printing assay for drug-dependent ribosome stalling was carried out
as described (Va´zquez-Laslop et al., 2008), with minor modifications. The
templates coding for the protein sequences under the control of T7 promoter
were generated by PCR. The templates (0.05–0.1 pmol) were used in a total
volume of 5 ml of the E. coli cell-free transcription-translation system assem-
bled from purified components (New England Biolabs). The reactions were
incubated for 15 min at 37C, followed by addition of the toe-printing primer
designed to anneal 100 nucleotides downstream from the anticipated ribo-
some stalling site. All the other procedures were carried out as previously
described.
Generation of the Tunnel Mutants and Protein Translation by the
Mutant Ribosomes
The mutations A2062G and U2609C were introduced in the 23S rRNA gene in
the pLK35 plasmid (Douthwaite et al., 1989). The mutant plasmids were trans-
formed into E. coli SQ171DtolC cells (Bollenbach et al., 2009). Plasmid
exchange was carried out following Zaporojets et al. (2003) and the mutant
ribosomes were prepared as described by Shimizu et al. (2005).
The in vitro translation of the fusA or yibA genes by wild-type and A2062U
mutant ribosomes was carried out in 5 ml reactions (Dribosome PURExpress,
New England Biolabs) containing 0.5 pmol of DNA templates and 15 pmol of
the ribosomes. After 45 min incubation at 37C in the presence or absence
of TEL (50 mM in the fusA-containing reaction or 10 mMduring yibA expression),
the reactions were stopped as described above and analyzed by SDS gel
electrophoresis.
For in vivo experiments, E. coli SQ171DtolC cells expressing wild-type
or mutant (A2062G or U2609C) ribosomes were grown in 10 ml of M9AA-M
media. Exponentially growing cultures were incubated with 100-fold
MIC (100 mg/ml) of ERY for 15 min prior to addition of 100 mCi of [35S]-
methionine, incubation of 3 min, and the subsequent addition of an excess
of L-methionine and incubation for 7 min. Cells were harvested by centrifuga-
tion and lysed by boiling in SDS gel loading buffer, and proteins were resolved
on 16.5% SDS gel.
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